In the 30%–50% of human cancers that retain wild-type p53, this loop is compromised, leading to a failure to properly restrain MDM2 and causing continuous limitation of p53 activity irrespective of activating signals (Wasylishen and Lozano 2016). This evidence concerns the gene TP53 and cancer.